Langerhans cell histiocytosis (LCH). Overview of symptoms of LCH, which may lead the patients to any of these medical specialists [0.03%]
朗格汉斯细胞组织细胞增生症(LCH)概述了LCH的症状，可能会导致患者看这些科室中的任何一个医生
Zdeněk Adam,Luděk Pour,Miroslav Tomíška et al.
Zdeněk Adam et al.
Langerhans cell histiocytosis (LCH) is a rare condition with incidence in adults 1-2/1 million, wherein Langerhans cells proliferate abnormally, adversely impacting organs including most frequently bones, skin, lungs, pituitary gland, lymph...
Pavol Fülöp,Marianna Dvorožňáková,Marianna Vachalcová et al.
Pavol Fülöp et al.
The gut microbiome is linked to the development of individual diseases. Patients with congestive heart failure (HF) develop intestinal wall edema due to venous congestion, which impairs absorption function and allows bacterial overgrowth. C...
Marek Lapka
Marek Lapka
Ascorbic acid is a well-described molecule which acts as a cofactor in many reactions and mediates a variety of biological functions. Despite its simple structure, vitamin C has a wide range of interesting effects that bring enormous potent...
Pituitary incidentaloma [0.03%]
垂体意外瘤
Michal Kršek
Michal Kršek
Pituitary incidentaloma are being accidentally found during imaging procedures in approximately 10% of normal population. Facing pituitary incidentalomas endocrinologists have to decide about further management based on the assessment of ho...
Jan Škrha Jr
Jan Škrha Jr
Dulaglutide is a frequently used GLP-1 analogue and one of the most potent antidiabetic drugs. Practical aspects of treatment with dulaglutide are presented in this article, together with new data from AWARD-11 study with higher concentrati...
Colorectal cancer in patients with diabetes - epidemiology, pathophysiology and applications for clinical practice [0.03%]
糖尿病患者的结直肠癌：流行病学、病理生理和临床实践应用
Alexandra Romanová,Jana Malinovská,Michala Lustigová et al.
Alexandra Romanová et al.
Diabetes mellitus (type 2 diabetes in particular) and colorectal carcinoma are relatively frequent diseases in our population. At the same time, these units share some common risk factors, for example obesity, lack of physical activity and ...
Anticoagulation in cancer patients; new recommendations based on randomized clinical trials [0.03%]
基于随机临床试验的癌症患者抗凝新建议
Dalibor Musil
Dalibor Musil
Venous thromboembolic disease (VTD) is currently the second leading cause of death in cancer patients with a prevalence of approximately 20% compared with that of 5% in the entire adult population. Cancer patients are a heterogeneous group ...
What do the new ESC Guidelines for the treatment of heart failure bring to internists? [0.03%]
2012年欧洲心力衰竭指南给内科医生带来什么？
Jindřich Špinar,Lenka Špinarová,Jiří Vítovec
Jindřich Špinar
Chronic heart failure is in european countries in 0,4-2,0% population with an increase with age. The improved care of acute cases enables to decrease the number of patients with chronic heart failure.The disease has a bad prognosis, the dia...
The position of SGLT2 inhibitors in current medical practice - update 2022 [0.03%]
SGLT2抑制剂的临床地位——2022年动态更新报告
Martin Prázný
Martin Prázný
Cardiovascular diseases are still the most common cause of mortality in patients with type 2 diabetes. Studies on the cardiovascular safety of new antidiabetic treatments, that have significantly expanded the treatment options for type 2 di...
Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice [0.03%]
口服司美格鲁肽（Rybelsus?）——临床实践中首个口服GLP-1受体激动剂
David Karásek
David Karásek
Glucagon like peptide-1 receptor agonists (GLP-1 RA) are potent antidiabetic drugs associated with significant weight loss and minimal risk of hypoglycemia. Semaglutide is a GLP-1 RA with a proven cardiovascular benefit. It is currently als...